Quite telling of the negativity that has taken hold of CYP sentiment, on HotCopper and in the market, that the progress in this report not even discussed, that did include new information on initial data from the DFU trial:
"Cynata recently released encouraging initial data from the first 6 patients with chronic DFUs. Initial analysis has shown average ulcer size decreased at a greater rate in all three patients who received CYP-006TK, Cynata’s unique topical mesenchymal stem cell (MSC) product, versus patients who only received standard of care. These preliminary results in the first 6 patients provide the Company with initial data toward demonstrating safety and efficacy of CYP-006TK, in chronic wounds."
Or as others have put it in a nice (pretty, it is after all a foot?) picture:
CYP Price at posting:
15.0¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)